CoChat

Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus

Open access

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

A major barrier to research on Parkinson's disease is inaccessibility of diseased tissue for study. One solution is to derive induced pluripotent stem cells from patients and differentiate them into neurons affected by disease. Triplication of SNCA, encoding α-synuclein, causes a fully penetrant, aggressive form of Parkinson's disease with dementia. α-Synuclein dysfunction is the critical pathogenic event in Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Here we produce multiple induced pluripotent stem cell lines from an SNCA triplication patient and an unaffected first-degree relative. When these cells are differentiated into midbrain dopaminergic neurons, those from the patient produce double the amount of α-synuclein protein as neurons from the unaffected relative, precisely recapitulating the cause of Parkinson's disease in these individuals. This model represents a new experimental system to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by α-synuclein dysfunction. Pluripotent stem cells can be generated from the somatic cells of humans and are a useful model to study disease. Here, pluripotent stem cells are made from a patient with familial Parkinson's disease, and the resulting neurons exhibit elevated levels of α-synuclein, recapitulating the molecular features of the patient's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms1453

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Multiple iPSC lines derived from a PD patient with SNCA triplication and an unaffected relative exhibit hallmarks of pluripotency. (a) Western blot analysis of AST and NAS fibroblasts confirms a lack of α-synuclein protein. Lysate of SH-SY5Y neuroblastoma cells transfected with an α-synuclein expressing plasmid was used as a positive control, and β-actin as a loading control. (b) Phase contrast images of AST and NAS fibroblasts and de novo iPSC colonies on SNL feeder cells at day 20 post-viral transduction. Scale bar, 100 μm. (c) Quantitative RT–PCR for retroviral transgene expression of the four reprogramming factors (Oct4, Sox2, c-Myc, Klf4). Expression in iPSC lines was normalized to transgene expression of NAS fibroblasts 3 days post-viral transduction (NAS VT). Also shown are negative controls: untransduced fibroblasts (NAS fibs) and human ESCs (Shef4 hESC). (d, e) Representative iPSC colonies derived from NAS fibroblasts (d) and AST fibroblasts (e) stained positive for the pluripotency markers OCT4, SSEA4, TRA-1-81 and NANOG. Scale bar, 100 μm. (f) Endogenous expression of OCT4, SOX2, NANOG and REX1 in two AST and two NAS iPSC lines, normalized to expression in human ESCs (Shef4), found a similar expression profile in all lines examined. Expression of these genes was absent in human fibroblasts (not shown). Error bars represent standard deviation of technical replicates, n=3.
Figure 1 Multiple iPSC lines derived from a PD patient with SNCA triplication and an unaffected relative exhibit hallmarks of pluripotency. (a) Western blot analysis of AST and NAS fibroblasts confirms a lack of α-synuclein protein. Lysate of SH-SY5Y neuroblastoma cells transfected with an α-synuclein expressing plasmid was used as a positive control, and β-actin as a loading control. (b) Phase contrast images of AST and NAS fibroblasts and de novo iPSC colonies on SNL feeder cells at day 20 post-viral transduction. Scale bar, 100 μm. (c) Quantitative RT–PCR for retroviral transgene expression of the four reprogramming factors (Oct4, Sox2, c-Myc, Klf4). Expression in iPSC lines was normalized to transgene expression of NAS fibroblasts 3 days post-viral transduction (NAS VT). Also shown are negative controls: untransduced fibroblasts (NAS fibs) and human ESCs (Shef4 hESC). (d, e) Representative iPSC colonies derived from NAS fibroblasts (d) and AST fibroblasts (e) stained positive for the pluripotency markers OCT4, SSEA4, TRA-1-81 and NANOG. Scale bar, 100 μm. (f) Endogenous expression of OCT4, SOX2, NANOG and REX1 in two AST and two NAS iPSC lines, normalized to expression in human ESCs (Shef4), found a similar expression profile in all lines examined. Expression of these genes was absent in human fibroblasts (not shown). Error bars represent standard deviation of technical replicates, n=3.CC BY-NC-SA · PubMed Central
Figure 2 Triplication region is maintained in patient-derived fibroblasts and iPSCs. (a) Quantitative genomic PCR for SNCA exons 1 and 4 demonstrates doubling of gene dosage in patient-derived AST iPSC lines when compared with NAS iPSC lines. Representative data shown. SNCA was normalized to β-globin (HBB) and β2-microglobulin (B2MG). (b) SNP profiles of chromosome 4q22 in DNA from unaffected relative blood, fibroblasts and iPSCs demonstrates that this region is normal. (c) The same region analysed in DNA from patient blood, fibroblasts and iPSCs confirms that the triplication region is present and is retained during reprogramming. (d) The triplication region is defined as chr4:89,375,425 to 90,880,891, spanning the following genes: HERC5, PIGY, HERC3, NAP1L5, FAM13AOS, FAM13A, TIGD2, GPRIN3, SNCA and MMRN1. LOC644248 is also in the triplication region but not yet defined by RefSeq. (e) Genome-wide SNP analysis of NAS9 iPSCs identified the following chromosomal abnormalities: a small deletion at the end of Chr4q, a duplication of part of Chr5q and an extended run of homozygosity occupying most of Chr12q.
Figure 2 Triplication region is maintained in patient-derived fibroblasts and iPSCs. (a) Quantitative genomic PCR for SNCA exons 1 and 4 demonstrates doubling of gene dosage in patient-derived AST iPSC lines when compared with NAS iPSC lines. Representative data shown. SNCA was normalized to β-globin (HBB) and β2-microglobulin (B2MG). (b) SNP profiles of chromosome 4q22 in DNA from unaffected relative blood, fibroblasts and iPSCs demonstrates that this region is normal. (c) The same region analysed in DNA from patient blood, fibroblasts and iPSCs confirms that the triplication region is present and is retained during reprogramming. (d) The triplication region is defined as chr4:89,375,425 to 90,880,891, spanning the following genes: HERC5, PIGY, HERC3, NAP1L5, FAM13AOS, FAM13A, TIGD2, GPRIN3, SNCA and MMRN1. LOC644248 is also in the triplication region but not yet defined by RefSeq. (e) Genome-wide SNP analysis of NAS9 iPSCs identified the following chromosomal abnormalities: a small deletion at the end of Chr4q, a duplication of part of Chr5q and an extended run of homozygosity occupying most of Chr12q.CC BY-NC-SA · PubMed Central
Figure 3 Patient and control iPSC lines differentiate efficiently into midbrain dopaminergic neurons. (a) Schematic of the dual SMAD inhibition/floor plate protocol used to promote differentiation of iPSCs to a midbrain dopaminergic fate. (b) Immunocytochemistry of neuralized AST and NAS iPSCs for TuJ1 (red) and tyrosine hydroxylase (TH – green) shows robust differentiation into dopaminergic neurons. Scale bar, 100 μm. (c) Counts of TH+ neurons, expressed as a percentage of TuJ1+ neurons (n=1955 total), found no significant difference in efficiency of dopaminergic differentiation between AST and NAS iPSCs. Error bars represent standard deviation of biological replicates, n=3. (d) LMX1B (green) is expressed in the majority of TH+ (red) neurons (>80%). A minority of TH+ cells are negative for LMX1B (arrowheads). Scale bar, 100 μm. (e) Quantitative RT–PCR analysis for midbrain dopaminergic neural markers (LMX1A, NURR1, TH and DAT) in AST and NAS neuronal cultures. To control for efficiency of neuralization we normalized expression to the pan-neuronal marker MAPT. Error bars represent standard deviation of technical replicates, n=3. (f) SNP analysis of AST-derived neurons confirms that the triplication region is retained intact following neuronal differentiation.
Figure 3 Patient and control iPSC lines differentiate efficiently into midbrain dopaminergic neurons. (a) Schematic of the dual SMAD inhibition/floor plate protocol used to promote differentiation of iPSCs to a midbrain dopaminergic fate. (b) Immunocytochemistry of neuralized AST and NAS iPSCs for TuJ1 (red) and tyrosine hydroxylase (TH – green) shows robust differentiation into dopaminergic neurons. Scale bar, 100 μm. (c) Counts of TH+ neurons, expressed as a percentage of TuJ1+ neurons (n=1955 total), found no significant difference in efficiency of dopaminergic differentiation between AST and NAS iPSCs. Error bars represent standard deviation of biological replicates, n=3. (d) LMX1B (green) is expressed in the majority of TH+ (red) neurons (>80%). A minority of TH+ cells are negative for LMX1B (arrowheads). Scale bar, 100 μm. (e) Quantitative RT–PCR analysis for midbrain dopaminergic neural markers (LMX1A, NURR1, TH and DAT) in AST and NAS neuronal cultures. To control for efficiency of neuralization we normalized expression to the pan-neuronal marker MAPT. Error bars represent standard deviation of technical replicates, n=3. (f) SNP analysis of AST-derived neurons confirms that the triplication region is retained intact following neuronal differentiation.CC BY-NC-SA · PubMed Central
Figure 4 Expression of α-synuclein in iPSC-derived neuronal cultures is heterogeneous. Expression of α-synuclein was observed in all TuJ1+ neurons derived from AST (a) and NAS (b) iPSCs. The majority of cells expressed low levels of α-synuclein (filled arrowheads) whereas 3–7% of TuJ1+ cells expressed a high level of protein (open arrowheads). Scale bar, 100 μm upper panels, 400 μm lower panels.
Figure 4 Expression of α-synuclein in iPSC-derived neuronal cultures is heterogeneous. Expression of α-synuclein was observed in all TuJ1+ neurons derived from AST (a) and NAS (b) iPSCs. The majority of cells expressed low levels of α-synuclein (filled arrowheads) whereas 3–7% of TuJ1+ cells expressed a high level of protein (open arrowheads). Scale bar, 100 μm upper panels, 400 μm lower panels.CC BY-NC-SA · PubMed Central
Figure 5 Gene expression profiling finds that the triplication genes are significantly enriched in AST iPSC-derived neurons. Principle components analysis (a) and hierarchical clustering (b) shows that iPSCs cluster with hESCs, while fibroblasts and neurons cluster separately. There is no clear separation between AST and NAS-derived cells at this level of analysis. (c) Scatter plots demonstrate that global gene expression of iPSCs is more similar to hESCs than fibroblasts and there are no significant differences in global gene expression between AST and NAS iPSCs. (d) Multiple views of a three-dimensional PCA plot, following batch effect removal, comparing iPSC gene expression to all hESC data sets on the Affymetrix U133 Plus 2.0 platform that are publicly available (59 samples from 8 separate submissions). The iPSCs intermingle within the hESC landscape in all three dimensions. (e) Gene set enrichment analysis for the triplication genes shows significant enrichment in AST iPSCs (nominal P-value <0.05) and neurons (nominal P-value <0.0001) but not fibroblasts (nominal P-value=0.09). Enrichment score P-values are estimated by using an empirical gene set-based permutation test procedure40. (f) SNCA expression is higher in AST-derived iPSCs and neurons than in equivalent cells from NAS.
Figure 5 Gene expression profiling finds that the triplication genes are significantly enriched in AST iPSC-derived neurons. Principle components analysis (a) and hierarchical clustering (b) shows that iPSCs cluster with hESCs, while fibroblasts and neurons cluster separately. There is no clear separation between AST and NAS-derived cells at this level of analysis. (c) Scatter plots demonstrate that global gene expression of iPSCs is more similar to hESCs than fibroblasts and there are no significant differences in global gene expression between AST and NAS iPSCs. (d) Multiple views of a three-dimensional PCA plot, following batch effect removal, comparing iPSC gene expression to all hESC data sets on the Affymetrix U133 Plus 2.0 platform that are publicly available (59 samples from 8 separate submissions). The iPSCs intermingle within the hESC landscape in all three dimensions. (e) Gene set enrichment analysis for the triplication genes shows significant enrichment in AST iPSCs (nominal P-value <0.05) and neurons (nominal P-value <0.0001) but not fibroblasts (nominal P-value=0.09). Enrichment score P-values are estimated by using an empirical gene set-based permutation test procedure40. (f) SNCA expression is higher in AST-derived iPSCs and neurons than in equivalent cells from NAS.CC BY-NC-SA · PubMed Central
Figure 6 SNCA expression is doubled in selected iPSC lines when controlling for efficiency of neuralization. (a) RT–PCR data for SNCA, SNCB and SNCG shows that expression of SNCA is significantly higher, and SNCG significantly lower, in AST iPSC-derived neurons when efficiency of neuralization is controlled for, by normalizing to expression of the pan-neuronal marker MAPT. Error bars represent standard deviation of technical replicates, n=3. ***P<0.0005; **P<0.005 (Student's t-test, unpaired, two-tailed). (b) Quantitative RT–PCR analysis of SNCA expression, normalized to pan-neuronal markers (NCAM, MAPT) to directly control for efficiency of differentiation, shows a twofold or greater increase in SNCA expression in neurons derived from AST iPSCs. Error bars represent standard deviation of technical replicates, n=3. (c) Western blot analysis of Day 20 neuronal cultures showed that AST18 expressed double the amount of α-synuclein protein as NAS2, despite differentiating into neurons with the same efficiency. (d) ELISA detects significantly more α-synuclein in 48 h conditioned media from AST neuronal cultures than equivalently conditioned media from NAS neuronal cultures. Error bars represent standard deviation of biological replicates, n=2.
Figure 6 SNCA expression is doubled in selected iPSC lines when controlling for efficiency of neuralization. (a) RT–PCR data for SNCA, SNCB and SNCG shows that expression of SNCA is significantly higher, and SNCG significantly lower, in AST iPSC-derived neurons when efficiency of neuralization is controlled for, by normalizing to expression of the pan-neuronal marker MAPT. Error bars represent standard deviation of technical replicates, n=3. ***P<0.0005; **P<0.005 (Student's t-test, unpaired, two-tailed). (b) Quantitative RT–PCR analysis of SNCA expression, normalized to pan-neuronal markers (NCAM, MAPT) to directly control for efficiency of differentiation, shows a twofold or greater increase in SNCA expression in neurons derived from AST iPSCs. Error bars represent standard deviation of technical replicates, n=3. (c) Western blot analysis of Day 20 neuronal cultures showed that AST18 expressed double the amount of α-synuclein protein as NAS2, despite differentiating into neurons with the same efficiency. (d) ELISA detects significantly more α-synuclein in 48 h conditioned media from AST neuronal cultures than equivalently conditioned media from NAS neuronal cultures. Error bars represent standard deviation of biological replicates, n=2.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 61 references

Cited by

Items 101–200 of 484

Metadata

Authors
Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W., Schapira, A. H., Gwinn, K., Hardy, J., Lewis, P. A., & Kunath, T.
Affiliations
  • MRC Centre for Regenerative Medicine (GB)
  • National Hospital for Neurology and Neurosurgery (GB)
  • Roslin Institute (GB)
  • University of Tsukuba (JP)
  • Baylor College of Medicine (US)
Corresponding author
  • Devine, Michael J.
  • Kunath, Tilo
Venue
Nature Communications
Published
2011-08-23
Volume
2
Issue
1
Pages
440-440
ISSN
2041-1723 (ISSN-L)
OpenAlex
W1985010554
Cited by
486
References
61
Citations by year
2026: 12 · 2025: 25 · 2024: 27 · 2023: 25 · 2022: 40 · 2021: 26 · 2020: 43 · 2019: 24 · 2018: 46 · 2017: 34 · 2016: 34 · 2015: 38 · 2014: 29 · 2013: 32 · 2012: 48
FWCI
22.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • ASEP (submittedVersion, public-domain)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Michael J. Fox Foundation for Parkinson's Research
  • University of Dundee
  • Wellcome Trust (089698)
  • Parkinson's UK (K-0911, G-4046, G-0907, F1002), F-0902)
  • Brain Research Trust
  • University of Sheffield
  • Medical Research Council (MC_G1000735)
  • Biotechnology and Biological Sciences Research Council (BBS/E/R/00001627, BBS/E/R/00001601)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
Parkinson's disease, induced pluripotent stem cells, alpha-synuclein, SNCA triplication, familial Parkinson's disease, midbrain dopaminergic neurons, disease modeling, neurodegeneration, multiple system atrophy, dementia with Lewy bodies, alpha-synuclein overexpression
MeSH terms
Cell Differentiation, Cells, Cultured, Humans, Neurons, Parkinson Disease, Gene Dosage, alpha-Synuclein, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.